There are 2789 resources available
942P - The role of intraoperative electron radiotherapy in centrally located hepatocellular carcinomas treated with narrow-margin (<1 cm) hepatectomy: A prospective, phase II study
Presenter: Liming Wang
Session: ePoster Display
Resources:
Abstract
943P - Long-term outcome of the oldest-old patients (85 years or older) underwent proton beam therapy for hepatocellular carcinoma
Presenter: Takashi Iizumi
Session: ePoster Display
944P - Adjuvant camrelizumab combined with apatinib treatment after resection of hepatocellular carcinoma in CNLC II and III stage: A single-center prospective phase II trial
Presenter: Xinrong Yang
Session: ePoster Display
946P - Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage C: A prospective, single-arm, phase II trial (TRIPLET study)
Presenter: Tian-Qi Zhang
Session: ePoster Display
947P - Updated survival and secondary safety and efficacy analyses from CA 209-678: A phase II open-label single-centre study of Y90-radioembolisation (Y90) in combination with nivolumab in Asian patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Joycelyn Lee
Session: ePoster Display
948P - Predicting the efficacy of lenvatinib plus anti-PD-1 antibodies in unresectable hepatocellular carcinoma (uHCC) using radiomics features of tumors extracted from baseline MRI
Presenter: Huichuan Sun
Session: ePoster Display
949P - Thermal ablation plus toripalimab in patients with advanced hepatocellular carcinoma: Phase I results from a multicenter, open-label, controlled phase I/II trial (IR11330)
Presenter: Liangrong Shi
Session: ePoster Display
950P - Ultra-sensitive and cost-effective method for early stage hepatocellular carcinoma and intrahepatic cholangiocarcinoma detection using plasma cfDNA fragmentomic profiles
Presenter: Xiangyu Zhang
Session: ePoster Display
887P - Final results and biomarker analysis from a phase I dose-expansion (part II) study of ISU104 (barecetamab; a novel anti-ErbB3) monotherapy or in combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Presenter: Sung-Bae Kim
Session: ePoster Display